Active substance Metyparone Holder Laboratoires HRA Pharma Status Closed Indication Endogenous Cushing’s syndrome in patients who have completed the study extension period of the PROMPT clinical trial with metyrapone Public documents Approbation Information for the patient Informed consent Last update 28/05/2021